<DOC>
	<DOCNO>NCT01314300</DOCNO>
	<brief_summary>Lidocaine 5 % plaster ( VERSATIS® 5 % ) show efficacy safety post-herpetic zoster adult pain . This treatment recommend first intention adult neuropathic pain allodynia . The purpose study assess efficacy safety lidocaine 5 % plaster ( VERSATIS® 5 % ) pediatric neuropathic pain vasoocclusive sickle cell crises pain .</brief_summary>
	<brief_title>Lidocaine 5 % Plasters ( Versatis® 5 % ) Pediatric Neuropathic Pains Vasoocclusive Sickle Cell Crisis Pains</brief_title>
	<detailed_description>Pediatric neuropathic pain infrequent . It 's difficult estimate prevalence . It may result several cause : infectious ( post-herpetic neuropathy ) , traumatic ( tumor Positional ) toxic ( chemotherapy radiotherapy ) . They often associate malignant pediatric disease . These pain spontaneous , continuous intermittent , type burn electric shock abnormal skin sensation ( hyperesthesia allodynia ) . Treatment adult : antiepileptic neuroleptic , sometimes associate analgesic ( level 2 3 ) . Lidocaine 5 % plaster use adult first line treatment reduce post-herpetic neuropathic pain , especially case mechanical allodynia . These plaster indicate symptomatic treatment post-herpetic neuropathic pain . Each plaster contain 700 mg lidocaine . It must apply painful area daily maximum period 12 hour per 24 hour . The primary endpoint evaluate efficacy lidocaine 5 % plaster ( VERSATIS 5 % ) 12 hour reduce pure mixed neuropathic pain reduce vasoocclusive sickle cell pain , localize , superficial , child , adolescent young adult . The secondary endpoint : 1. evaluate efficacy lidocaine 5 % plaster ( VERSATIS 5 % ) 6 hour reduce pure mixed neuropathic pain reduce vasoocclusive sickle cell pain , localize , superficial , child , adolescent young adult . 2. evaluate safety lidocaine 5 % plaster ( VERSATIS® 5 % ) indication .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>6 year &lt; = Age &lt; = 21 year With : Pure mixed , localized , superficial neuropathic pain neuropathic pain score DN4 great equal 4 Or localize , superficial sickle cell crisis pain Insufficiently relieve commonly use therapeutic ( analgesic level II III / antiepileptic drug , / neuroleptic ) GCS &gt; 12 Covered medical insurance Signed write informed consent form ( minor unemancipated , permission give holder parental authority ) Clinical condition permit data reporting ( impaired consciousness ) Painful area surface great : 150 cm² patient total body surface area &lt; 1 m² 300 cm² patient 1 m² &lt; total body surface area &lt; 1.5 m² 450 cm² patient total body surface area &gt; 1.5 m² Existence statement use lidocaine 5 % ( VERSATIS® 5 % ) plaster define summary product characteristic , : know hypersensitivity active substance excipients know hypersensitivity local anesthetic amide ( eg bupivacaine , etidocaine , mepivacaine prilocaine ) inflammatory injure skin ( active lesion herpes zoster , dermatitis wound ) Severe cardiac insufficiency Severe renal insufficiency Severe hepatic insufficiency Patient receive antiarrhythmic class I local anesthetic . Pregnant lactate female female childbearing potential employ adequate contraception Patient include another clinical trial management pain</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Child , adolescent , young adult</keyword>
	<keyword>Plaster</keyword>
	<keyword>Lidocaine</keyword>
</DOC>